Drug–nutrient interactions

Geriatric Gastroenterology

Volumn , Issue , 2012, Pages 89-98

  Gunturu, Srinivas Guptha ^a   Dharmarajan, T S ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922729617     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-1623-5_10     Document Type: Chapter

References (102)

1. Chan LN. Drug nutrient interactions in clinical nutrition. Curr Opin Clin Nutr Metab Care. 2002;5:327-32.
2. Lourenco R. Enteral feeding: drug/nutrient interaction. Clin Nutr. 2001;20(2): 187-93.
3. Chan LN. Drug-nutrient interactions in transplant recipients. J Parenter Enteral Nutr. 2001;25(3):132-41.
4. Ward LS. The difficult patient: drug interactions and the influence of concomitant diseases on the treatment of hypothyroidism. Arq Bras Endocrinol Metabol. 2010;54(5):435-42.
5. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509-33.
6. Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(5):274-7.
7. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165-77.
8. Zarowitz BJ. Pharmacologic consideration of commonly used gastrointestinal drugs in the elderly. Gastroenterol Clin North Am. 2009;38(3):547-62.
9. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-7.
10. http://www.chiro.org/nutrition/ABSTRACTS/Nutrient_ Depletion. shtml. Accessed 3 Jan 2011.
11. McLean AJ. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163-84.
12. McCabe BJ. Prevention of food-drug interactions with special emphasis on older adults. Curr Opin Clin Nutr Metab Care. 2004;7:21-6.
13. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582): 185-91.
14. Utermohlen V. Nutrient-drug interactions. Encyclopedia of Food and Culture. 2003. http://www.encyclopedia.com/doc/1G2-3403400440.html. Accessed 23 Jan 2011.
15. Sorenson JM. Herb-drug, food-drug, nutrient-drug and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med. 2002;8(3):293-308.
16. Dharmarajan TS, Pitchumoni CS, Kokkat AJ. The aging gut. Pract Gastroenterol. 2001;25:15-27.
17. Akamine D, Filho MK, Peres CM. Drug nutrient interactions in elderly people. Curr Opin Clin Nutr Metab Care. 2007;10: 304-10.
18. Armbrecht HJ, Boltz MA, Kumar VB. Intestinal plasma membrane calcium pump protein and its induction by 1,25 (OH)2D3 decrease with age. Am J Physiol Gastrointest Liver Physiol. 1999;277:G41-7.
19. Toyoshima M, Inada M, Kameyama M. Effects of aging on intracellular transport of vitamin B12 (B12) in rat enterocytes. J Nutr Sci Vitaminol (Tokyo). 1983;29(1):1-10.
20. Custodio J, Wu C, Benet L. Predicting drug disposition, absorp- tion/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717-33.
21. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8): 843-53.
22. Genser D. Food and drug interaction: consequences for the nutri- tion/health status. Ann Nutr Metab. 2008;52(1):29-32.
23. Alemdaroglu NC, Dietz U, Wolffram S, Spahn-Langguth H, Langguth P. Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm Drug Dispos. 2008;29(6): 335-48.
24. Simon Z. The effect of milk components, especially of casein, on the bioavailability of ciprofloxacin tablets cannot be evaluated by dissolution testing. J Pharm Biomed Anal. 2010;53(3):819.
25. De Lemos ML, Hamata L, Jennings S, Leduc T. Interaction between mercaptopurine and milk. J Oncol Pharm Pract. 2007;13(4):237-40.
26. Mulligan GB, Licata A. Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. J Bone Miner Res. 2010;25(4):928-30.
27. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62(10): 1481-502.
28. Gauthier I, Malone M. Drug-food interactions in hospitalised patients. Methods of prevention. Drug Saf. 1998;18(6):383-93.
29. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor-evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29(8):824-33.
30. Gregory C. Drug and enteral feed interactions. J Hum Nutr Diet. 2006;19(3):237-9.
31. Kim T-E, Kim B-H, Kim J-R, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009;68(1):43-6.
32. Khosravan R, Grabowski B, Wu J-T, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008;65(3):355-63.
33. Fernandez R, Phillips SF. Components of fiber bind iron in vitro. Am J Clin Nutr. 1982;35(1):100-6.
34. Floren CH, Nilsson A. Binding of bile salts to fibre-enriched wheat fibre. Scand J Gastroenterol Suppl. 1987;129:192-9.
35. Heaney RP, Weaver CM. Effect of psyllium on absorption of coingested calcium. J Am Geriatr Soc. 1995;43(3):261-3.
36. Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10(2):282-8.
37. Pelton R, LaValle JB, Hawkins EB, Krinsky DL. Drug-induced nutrient depletion handbook: 1999-2000. Hudson: Lexi-comp; 1999.
38. Mason P. Important drug-nutrient interactions. Proc Nutr Soc. 2010;69(4):551-7.
39. Henley E. Sorbitol-based elixirs, diarrhea and enteral tube feeding. Am Fam Physician. 1997;55(6):2084; 2086.
40. Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab. 2010; 11 (2): 171-81.
41. Bressler R. Herb-drug interactions: interactions between ginseng and prescription medications. Geriatrics. 2005;60(8):16-7.
42. Bressler R. Herb-drug interactions. Interactions between saw palmetto and prescription medications. Geriatrics. 2005; 60(11):32-34.
43. Wittkowsky AK. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis. 2008;25(1):72-7.
44. Ansell J, McDonough M, Zhao Y, Harmatz JS, Greenblatt DJ. The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J Clin Pharmacol. 2009;49(7):824-30.
45. Hamann GL, Campbell JD, George CM. Warfarin-cranberry juice interaction. Ann Pharmacother. 2011;45(3):e17.
46. Dharmarajan L, Dharmarajan TS. Prescribing warfarin appropriately to meet Patient Safety Goals. Am Health Drug Benefits. 2008;1(6):26-32.
47. Moore AA, Blow FC, Hoffing M, et al. Primary care-based intervention to reduce at-risk drinking in older adults: a randomized controlled trial. Addiction. 2011;106(1):111-20.
48. Hamid A, Kaur J. Long-term alcohol ingestion alters the folatebinding kinetics in intestinal brush border membrane in experimental alcoholism. Alcohol. 2007;41(6):441-6.
49. Hamid A, Wani NA, Kaur J. New perspectives on folate transport in relation to alcoholism-induced folate malabsorption - association with epigenome stability and cancer development. FEBS J. 2009;276(8):2175-91.
50. Gilbert RM. Caffeine consumption. Prog Clin Biol Res. 1984;158:185-213.
51. Nehlig A. Are we dependent upon coffee and caffeine a review on human and animal data. Neurosci Biobehav Rev. 1999;23:563-76.
52. Rapuri P, Gallagher J, Nawaz Z. Caffeine decreases vitamin D receptor protein expression and 1,25(OH)2D3 stimulated alkaline phosphatase activity in human osteoblast cells. J Steroid Biochem Mol Biol. 2007;103(3-5):368-71.
53. Korpelainen R, Korpelainen J, Heikkinen J, et al. Lifestyle factors are associated with osteoporosis in lean women but not in normal and overweight women: a population-based cohort study of 1222 women. Osteoporos Int. 2003;14(1):34-43.
54. Hallstrom H, Wolk A, Glynn A, Michaelsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int. 2006;17(7):1055-64.
55. Eadie MJ. Clinically signi fi cant drug interactions with agents specific for migraine attacks. CNS Drugs. 2001;15(2):105-18.
56. Jankiewicz K, Chroscinska-Krawczyk M, Blaszczyk B, Czuczwar SJ. Caffeine and antiepileptic drugs: experimental and clinical data. Przegl Lek. 2007;64(11):965-7.
57. Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther. 2007;82(1):54-62.
58. Hegarty VM, May HM, Khaw K. Tea drinking and bone mineral density in older women. Am J Clin Nutr. 2000;71:1003-7.
59. Chen Z. Habitual tea consumption and risk of osteoporosis: a prospective study in the women’s health initiative observational cohort. Am J Epidemiol. 2003;158(8):772-81.
60. Devine A, Hodgson JM, Dick IM, Prince RL. Tea drinking is associated with benefits on bone density in older women. Am J Clin Nutr. 2007;86:1243-7.
61. Cooper M, Safran M, Eberhardt M. Caffeine consumption among adults on benzodiazepine therapy: United States 1988-1994. Psychol Rep. 2004;95(1):183-91.
62. Houston MC. Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev Cardiovasc Ther. 2010;8(6):821-33.
63. Brosen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol. 1998;13 Suppl 5:S45-7.
64. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest. 2011;139(5):1130-9.
65. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36(6):425-38.
66. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-21.
67. Vitamin D. 2010. http://www.nlm.nih.gov/medlineplus/druginfo/natural/929.html. Accessed 27 Jan 2011.
68. Dharmarajan TS, Norkus EP. Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? Nat Clin Pract Gastroenterol Hepatol. 2008;5(11):604-5.
69. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448-57.
70. Stover PJ. Vitamin B12 and older adults. Curr Opin Clin Nutr Metab Care. 2010;13(1):24-7.
71. Liu KW. Metformin-related vitamin B12 deficiency. Age Ageing. 2006;35(2):200-1.
72. Ezra A, Hoffman A, Breuer E, et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem. 2000;43:3641-52.
73. Mitchell DY, Eusebio RA, Sacco-Gibson NA. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol. 2000;40(3): 258-65.
74. Gertz BJ, Holland SD, Kline WF. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288-98.
75. Umland EM, Boyce EG. Risedronate a new oral bisphosphonate. Clin Ther. 2001;24(5):835-6.
76. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347-57.
77. Beckwith MC, Feddema SS, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm. 2004;39(3): 225-37.
78. Brown RO, Dickerson RN. Drug nutrient interactions. Am J Manag Care. 2000;5(3):345-55.
79. Klang M, Graham D, McLymont V. Warfarin bioavailability with feeding tubes and enteral formula. J Parenter Enteral Nutr. 2010;34(3):300-4.
80. Muramatsu RS, Litzinger MHJ, Fisher E, Takeshita J. Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am J Geriatr Pharmacother. 2010;8(2):98-114.
81. Wohlt PD, Zheng L, Gunderson S, et al. Recommendations for the use of medications with continuous enteral nutrition. Am J Health Syst Pharm. 2009;66(16):1458-67.
82. Mirtallo JM. Complications associated with drug and nutrient interactions. J Infus Nurs. 2004;27(1):19-24.
83. Gardiner P, Graham R, Legedza ATR, et al. Factors associated with herbal therapy use by adults in the USA. Altern Ther Health Med. 2007;13:22-9.
84. Bent S. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116(7):478-85.
85. Nowack R. Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John’s wort—and beyond! (review article). Nephrology. 2008;13(4):337-47.
86. Boobis A, Watelet J-B, Whomsley R, et al. Drug interactions. Drug Metab Rev. 2009;41(3):486-527.
87. Sica D. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens. 2006;19(7):768-73.
88. Dharmarajan TS, Pitchumoni CS. Drug-nutrient interactions in older adults. Pract Gastroenterol. 2002;26(4):37-55.
89. Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther. 2010;88(3): 339-42.
90. Lin C, Ke X, Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology. 2008; 110(3): 145-52.
91. Hammerness P, Basch E, Ulbricht C, et al. St John’s wort a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44:271-82.
92. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (hypericum perforatum) drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54:349-56.
93. Han H-K. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin Drug Metab Toxicol. 2011;7(6):721-9.
94. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s wort, ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136:42-53.
95. Sanchez-Muniz FJ, Bastida S, Gutierrez-Garcia O, Carbajal A. Olive oil-diet improves the simvastatin effects with respect to sunflower oil-diet in men with increased cardiovascular risk: a preliminary study. Nutr Hosp. 2009;24(3):333-9.
96. Ovesen L, Lyduch S, Idorn ML. The effect of a diet rich in brussels sprouts on warfarin pharmacokinetics. Eur J Clin Pharmacol. 1988;33:521-3.
97. Deferme S, Mols R, Van Driessche W, Augustijns P. Apricot extract inhibits the P-gp-mediated efflux of talinolol. J Pharm Sci. 2002;91(12):2539-48.
98. Al-Ghazawi MA, Tutunji MS, Abu Ruz SM. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur J Clin Pharmacol. 2010; 66(2): 159-63.
99. Houston MC. The role of cellular micronutrient analysis, nutra- ceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis. 2010;4(3):165-83.
100. Pae C, Lim H, Han C, Neena A, Lee C, Patkar A. Selegiline transdermal system: current awareness and promise. ProgNeuropsychopharmacol Biol Psychiatry. 2007;31(6):1153-63.
101. Bush TM, Rayburn KS, Holloway SW, et al. Adverse interactions between herbal and dietary substances and prescription medications a clinical survey. Altern Ther Health Med. 2007;13(2): 30-5.
102. Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000;34:1478-82.